Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-institution Phase I/Ib Study of Ibrutinib With ABT-199 in Relapsed/Refractory Mantle Cell Lymphoma

NCT02419560 is registered in ClinicalTrials.gov with Craig Portell, MD as lead sponsor.

NCT NCT02419560
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02419560 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-institution Phase I/Ib Study of Ibrutinib With ABT-199 in Relapsed/Refractory Mantle Cell Lymphoma
Lead sponsor
Craig Portell, MD
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2015
Completion date
May 31, 2021
Enrollment
37 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, mantle-cell, recurrent lymphoma, mantle-cell